Informations générales (source: ClinicalTrials.gov)
Angiogenic Function at Normal Term on Placenta (ANNOTEP)
Observational
Centre Hospitalier Intercommunal Creteil (Voir sur ClinicalTrials)
mars 2019
mars 2029
29 juin 2024
In vivo and ex vivo study of trophoblastic angiogenic trophoblastic function in placentas
from normal pregnancies, at term
Etablissements
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CHI DE CRETEIL | Lecarpentier Edouard, MD | Contact (sur clinicalTrials) | |||
Critères
Femme
Inclusion Criteria:
- Pregnancies with scheduled cesarean delivery >37 weeks of amenorrhea:
- strictly normal pregnancies
- complicated pregnancies of gestational diabetes, insulin-treated or not
- complicated pregnancies due to pregnancy cholestasis
- spontaneous or in vitro fecondation (IVF) / Intracytoplasmic sperm injection (ICSI)
pregnancies with or without oocyte donation
- Pregnancies with scheduled cesarean delivery >37 weeks of amenorrhea:
- strictly normal pregnancies
- complicated pregnancies of gestational diabetes, insulin-treated or not
- complicated pregnancies due to pregnancy cholestasis
- spontaneous or in vitro fecondation (IVF) / Intracytoplasmic sperm injection (ICSI)
pregnancies with or without oocyte donation
- Patient's opposition
- Age < 18 years old
- Women under the protection of justice
- Multiple pregnancy
- Known major fetal malformation
- Pre-eclampsia and intrauterine growth retardation
- Placental insertionnomaly
- Type 1 diabetes
- HIV-positive patient with HIV/hepatisis C virus (HCV) regardless of viral load
- Patient in labour at the time of Caesarean section
- Patient whose medical history results in medication being taken in pregnancy courses
that may interfere with the biology of the trophoblast (immunomodulators in case of
autoimmune diseases, anti-rejection drugs in case of transplant patients)